Access the full text.
Sign up today, get DeepDyve free for 14 days.
H. Walczak, Robert Miller, K. Ariail, B. Gliniak, T. Griffith, M. Kubin, Wilson Chin, Jon Jones, A. Woodward, Tiep Le, Craig Smith, P. Smolak, R. Goodwin, C. Rauch, J. Schuh, D. Lynch (1999)
Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivoNature Medicine, 5
P. Golstein (1997)
Cell death: TRAIL and its receptors.Current biology : CB, 7 12
G. Pan, K. O’Rourke, A. Chinnaiyan, R. Gentz, R. Ebner, Jian Ni, V. Dixit (1997)
The Receptor for the Cytotoxic Ligand TRAIL, 276
J. Ogasawara, Rie Watanabe‐Fukunaga, M. Adachi, A. Matsuzawa, T. Kasugai, Y. Kitamura, N. Itoh, T. Suda, S. Nagata (1993)
Lethal effect of the anti-Fas antibody in miceNature, 364
S. Lee, S. Kim, J. Lee, M. Shin, S. Dong, E. Na, W. Park, K. Kim, C. Kim, S. Kim, N. Yoo (1998)
Detection of soluble Fas mRNA using in situ reverse transcription-polymerase chain reaction.Laboratory investigation; a journal of technical methods and pathology, 78 4
S. Wiley, K. Schooley, P. Smolak, W. Din, Changwei Huang, J. Nicholl, G. Sutherland, T. Smith, C. Rauch, Craig Smith, R. Goodwin (1995)
Identification and characterization of a new member of the TNF family that induces apoptosis.Immunity, 3 6
J. O'Connell, G. O'sullivan, J. Collins, F. Shanahan (1996)
The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligandThe Journal of Experimental Medicine, 184
S. Nagata (1997)
Apoptosis by Death FactorCell, 88
R. Bargou, C. Wagener, K. Bommert, M. Mapara, P. Daniel, W. Arnold, M. Dietel, H. Guski, A. Feller, H. Royer, B. Dörken (1996)
Overexpression of the death-promoting gene bax-alpha which is downregulated in breast cancer restores sensitivity to different apoptotic stimuli and reduces tumor growth in SCID mice.The Journal of clinical investigation, 97 11
J. O'Connell, M. Bennett, G. O'sullivan, J. O’Callaghan, J. Collins, F. Shanahan (1999)
Expression of Fas (CD95/APO-1) Ligand by Human Breast Cancers: Significance for Tumor Immune PrivilegeClinical Diagnostic Laboratory Immunology, 6
H. Rabinowich, T. Reichert, Y. Kashii, B. Gastman, M. Bell, T. Whiteside (1998)
Lymphocyte apoptosis induced by Fas ligand- expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes.The Journal of clinical investigation, 101 11
H. Vollmers, J. Dämmrich, F. Hensel, H. Ribbert, A. Meyer‐Bahlburg, Tobias Ufken‐Gaul, Marlene Korff, H. Müller-hermelink (1997)
Differential expression of apoptosis receptors on diffuse and intestinal type stomach carcinomaCancer, 79
A. Ashkenazi, R. Pai, S. Fong, Susan Leung, David Lawrence, S. Marsters, Christine Blackie, Ling Chang, Amy McMurtrey, Andrea Hebert, L. Deforge, I. Koumenis, D. Lewis, Louise Harris, J. Bussiere, H. Koeppen, Z. Shahrokh, R. Schwall (1999)
Safety and antitumor activity of recombinant soluble Apo2 ligand.The Journal of clinical investigation, 104 2
T. Griffith, Wilson Chin, Glenn Jackson, D. Lynch, M. Kubin (1998)
Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells.Journal of immunology, 161 6
Maccon Keane, S. Ettenberg, Geoffrey Lowrey, Edward Russell, S. Lipkowitz (1996)
Fas expression and function in normal and malignant breast cell lines.Cancer research, 56 20
T. Reimer, D. Koczan, H. Müller, K. Friese, A. Krause, H. Thiesen, B. Gerber (2000)
Human chorionic gonadotrophin-beta transcripts correlate with progesterone receptor values in breast carcinomas.Journal of molecular endocrinology, 24 1
G. Niehans, Thomas Brunner, S. Frizelle, Jacob Liston, Christopher Salerno, Dennis Knapp, D. Green, R. Kratzke (1997)
Human lung carcinomas express Fas ligand.Cancer research, 57 6
J. Rieger, H. Ohgaki, P. Kleihues, Michael Weller (1999)
Human astrocytic brain tumors express APO2L/TRAILActa Neuropathologica, 97
S. Strand, W. Hofmann, H. Hug, Martina Müller, G. Otto, D. Strand, S. Mariani, W. Stremmel, P. Krammer, P. Galle (1996)
Lymphocyte apoptosis induced by CD95 (APO–1/Fas) ligand–expressing tumor cells — A mechanism of immune evasion?Nature Medicine, 2
M. Bennett, J. O'Connell, Gerald O'sullivan, C. Brady, D. Roche, J. Collins, F. Shanahan (1998)
The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma.Journal of immunology, 160 11
R. Pitti, S. Marsters, S. Ruppert, C. Donahue, A. Moore, A. Ashkenazi (1996)
Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family*The Journal of Biological Chemistry, 271
Apoptosis-inducing ligands such as Fas ligand (FasL) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) have been found to play an important role in cell regulation. Different malignant tumors show an altered expression of these ligands and their respective receptors compared to normal tissues. The purpose of this study was therefore to investigate expression of TRAIL, FasL, and its receptor Fas on protein and mRNA levels in breast carcinomas ( n =40), fibroadenomas ( n =7), and normal breast tissues ( n =5). Immunohistochemical reaction demonstrated that FasL was strongly expressed in breast cancer tissues (34/40) while only one fibroadenoma and one normal breast tissue reacted weakly positive for FasL. All fibroadenomas and normal breast tissues as well as the majority of breast cancer tissues expressed Fas on protein level. Quantitative RT-PCR analysis detected high expression of FasL mRNA in breast cancer tissues and fibroadenomas, whereas fibroadenomas showed the highest Fas mRNA copy numbers, followed by breast cancer tissues and normal breast tissues ( P <0.05). Compared to FasL expression, TRAIL could be detected in less breast cancer tissues on protein level (21/40) and was found in only one fibroadenoma and none of the normal breast tissues. Thus, it can be concluded that malignant breast tumors show an altered expression of the two apoptosis-inducing ligands FasL and TRAIL.
Histochemistry and Cell Biology – Springer Journals
Published: Mar 1, 2000
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.